Regeneron Reports Q1 2026 Earnings with Revenue Growth and Product Performance Highlights
Regeneron (REGN) reported Q1 2026 earnings with total revenues of $3.6 billion, a 19% increase, driven by Sanofi collaboration revenue and strong sales of EYLEA HD and Libtayo. Non-GAAP diluted earnings per share rose 15% to $9.47, with net income reaching $1 billion. The company noted mixed performance across its products, with EYLEA HD showing strong growth while EYLEA sales declined due to conversion to the newer version and competition.
Tickers: $REGN
Topics: Earnings Financial Results Pharmaceuticals Revenue Stock Performance